Our Entrepreneurs

Rare Genomics

Jimmy Lin & Scott Taing

Dr. Cheng-Ho Jimmy Lin, MD, PhD, MHS is the the Chief Scientific Officer (CSO), Oncology at Natera (NASDAQ: NTRA), where he is leading the development of new diagnostic technologies for cancer. Dr. Lin is also a 2016 Senior TED Fellow and Founder & President of Rare Genomics Institute, the world's first platform to enable any community to leverage cutting- edge biotechnology to advance understanding of any rare disease. Previously, Dr. Lin led the ClinOmics program in the Genetics Branch of the National Cancer Institute (NIH/NCI). Prior to this, he led the computational analysis of the first ever exome sequencing studies of cancer at Johns Hopkins and was a research instructor at Washington University in St. Louis. He has numerous publications in Science, Nature, Cell, Nature Genetics, and Nature Biotechnology, and has been featured in Forbes, Bloomberg, Wall Street Journal, New York Times, Washington Post, BBC, TIME, and the Huffington Post.

 


 

Scott is the data curator for the modENCODE chromatin group through the Lui Lab of the Dana Farber Cancer Institute and Harvard School of Public Health. His interests are developing systems and tools to scale the analysis and visualization of genomics data. He did graduate level work at Johns Hopkins and Nanjing University and holds a bachelors degree from Yale University.

Rare Genomics is an international 501(c) 3 non-profit that makes cutting edge research technologies of genome sequencing, physicians and scientists around the world accessible to rare disease patients. Rare Genomics helps families source, design and fund personalized research projects for diseases not otherwise studied helping rare disease patients find hope for a cure. By providing an expert network and an online crowdfunding mechanism Rare Genomics works alongside patients and their families, providing them with the necessary tools, knowledge, and connections so that they can better understand the cause of their disease.

Website